{"id":64271,"date":"2025-10-30T16:17:28","date_gmt":"2025-10-30T20:17:28","guid":{"rendered":"https:\/\/www.psi.org\/?page_id=64271"},"modified":"2025-11-05T13:35:21","modified_gmt":"2025-11-05T18:35:21","slug":"psi-at-astmh-2025","status":"publish","type":"page","link":"https:\/\/www.psi.org\/fr\/psi-at-astmh-2025\/","title":{"rendered":"PSI at ASTMH 2025"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

9 - 13 November 2025<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Join PSI at
ASTMH 2025<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Learn how PSI and our partners are advancing science and systems to end malaria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

How can evidence and innovation accelerate progress toward ending malaria?<\/strong><\/p>

PSI is sharing research and learnings from Benin, Cameroon, C\u00f4te d\u2019Ivoire, Democratic Republic of the Congo, Ghana, Madagascar, <\/span>Mozambique, Zambia, and Zanzibar<\/span>\u2014showcasing how country-led innovation and stronger data systems are improving malaria prevention, diagnosis, and treatment. Together with partners, we\u2019re strengthening the evidence base and translating data into action to build more resilient, equitable malaria programs.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Side Event<\/span> <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Monday, NOVEMBER 10<\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

A new way to track antimalarial consumption in Africa: Live Demo of Maisha ACT<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
SESSION DESCRIPTION <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This event will feature a live demonstration of Maisha ACT\u2019s interactive dashboards, showing how to explore the malaria supply chain from raw materials to the finished products reaching patients at the last mile. Attendees will see firsthand how the tool reveals consumption trends across geographies, product choices, pricing, and quality. Maisha ACT opens a critical new window into the private sector, which distributes the majority of antimalarials in many African countries, offering that is often a broader and more timely complement to existing public sector data. This provides a fuller picture needed to guide research, strategy, and impact.<\/p>

The session will include a panel discussion \u2013 “Implications of novel data and research for drug-resistant malaria”<\/strong> \u2013 exploring current work, key trends, data gaps, and next steps for developing an effective response to antimalarial resistance in Africa. It will be followed by lightning talks showcasing real-world examples<\/strong> of how organizations are closing the data gap with Maisha ACT, using it for market intelligence, product launches, and insights on demand, pricing, and competition.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

TIME
<\/strong>10:00 AM to 12:00 PM EASTERN<\/p>

LOCATION
<\/strong>InterContinental Toronto Centre (225 Front St W)
Room Ontario\/Niagara Rooms (Lower Level)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tLEARN MORE<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Scientific<\/br>Symposium<\/span> <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

tuesday, NOVEMBER 11<\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Results from Large-scale Implementation of Perennial Malaria Chemoprevention (PMC) in Benin, Cameroon, C\u00f4te d'Ivoire, Mozambique and Nigeria<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
SESSION DESCRIPTION <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

How can evidence and innovation accelerate progress toward ending malaria?<\/strong>
PSI is sharing research and learnings from Benin, Cameroon, C\u00f4te d\u2019Ivoire, and Mozambique\u2014showcasing how country-led innovation and stronger data systems are improving malaria prevention, diagnosis, and treatment. Together with our partners, we\u2019re strengthening the evidence base and translating data into action to build more resilient, equitable malaria programs.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

TIME
<\/strong>4:00 PM – 5:45 PM EASTERN<\/p>

LOCATION
<\/strong>Convention Center
Room 718B (Level 7)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tLEARN MORE<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

ORAL & POSTER<\/br>PRESENTATIONS<\/span> <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/path><\/svg><\/span>\n\t\t\t\t\t\t\t\t<\/path><\/svg><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tNovember 10<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Oral Presentations<\/strong><\/p>

(6015) Private Sector Case Management in Nigeria: Findings from the 2024 ACTwatch Lite Survey<\/p>

Session: 5 \u2013\u00a0Malaria \u2013 Surveillance and Data Use<\/a><\/p>

8:30 AM Eastern\u00a0<\/p>

Convention Center \u2013 Room 701B (Level 7)<\/p>

More information<\/a><\/p>

(6090) Innovations in mobile data capture for multi-country implementation of a longitudinal malaria chemoprevention study in Cameroon and Cote d\u2019Ivoire<\/p>

Session: 27 \u2013 Global Health: Improved Health Care Service Delivery and Health Systems Strengthening<\/a><\/p>

10:55 AM Eastern<\/p>

Convention Center \u2013 Room 801A (Level 8)<\/p>

More information<\/a><\/p>

Poster Presentations<\/strong><\/p>

(6315) Surveillance of antimalarial resistance markers to inform SP suitability for perennial malaria chemoprevention in C\u00f4te d\u2019Ivoire<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6317) Mapping antimalarial drug resistance markers in Plasmodium falciparum isolates across Benin<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6342) Utilizing the WHO Malaria Surveillance Assessment Toolkit to Accelerate Elimination in Zanzibar<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8 Poster Hall)<\/p>

See abstract<\/a><\/p>

(6393) Social determinants of health and the risk of malaria infection in a cohort study of perennial malaria chemoprevention in Cameroon: A causal mediation analysis<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6402) Health Worker Perceptions of Malaria Vaccine and Perennial Malaria Chemoprevention Co-implementation<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6411) Do three additional PMC doses affect uptake of vitamin A supplementation in Cameroon? A novel comparative-interrupted time series analysis<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6416) Integrating evidence from novel chemoprevention trials to estimate protective efficacy of sulfadoxine-pyrimethamine against malaria parasites across different sub-Saharan Africa resistance profiles.<\/p>

12:30 PM Eastern<\/p>

Poster Session A<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/path><\/svg><\/span>\n\t\t\t\t\t\t\t\t<\/path><\/svg><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tNovember 11<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Oral Presentations<\/strong><\/p>

(7167) Barriers to Essential Programme on Immunisation Coverage and Implications for Perennial Malaria Chemoprevention in Infants: Evidence from census surveys in Cameroon and C\u00f4te d\u2019Ivoire<\/p>

Session: 92 \u2013 Global Health: Women\u2019s, Maternal, Newborn, Child, and Adolescent Health<\/a><\/p>

2:55 PM Eastern<\/p>

Convention Center \u2013 Room 801A (Level 8)<\/p>

More information<\/a><\/p>

(7190) Geographical Variation in Sulfadoxine-Pyrimethamine Resistance Markers and Implications for Malaria Chemoprevention in Cameroon<\/p>

Session: 98 \u2013 Malaria \u2013 Current Trends in Antimalarial Drug Resistance<\/a><\/p>

4:10 PM Eastern<\/p>

Convention Center \u2013 Room 701B (Level 7)<\/p>

More information<\/a><\/p>

Poster Presentations<\/strong><\/p>

(6710) An interactive user-editable web-based app to inform context-adapted, cost-effective policy choices in heterogeneous settings: The perennial malaria chemoprevention decision support tool.<\/p>

12:00 PM Eastern<\/p>

Poster Session B<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6877) Prevalence of Pfdhps and Pfdhfr genetic markers associated with antimalarial drug resistance in two temporal cohorts in the Democratic Republic of Congo and implications for chemoprevention<\/p>

12:00 PM Eastern<\/p>

Poster Session B<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6880) Nationwide Surveillance of Molecular Markers of Antimalarial Resistance in Ghana<\/p>

12:00 PM Eastern<\/p>

Poster Session B<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6961) The secondary benefits of providing malaria chemoprevention to infants and children<\/p>

12:00 PM Eastern<\/p>

Poster Session B<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(6983) Reaching children in the second year of life with perennial malaria chemoprevention (PMC): Opportunities and challenges from Benin, C\u00f4te d\u2019Ivoire and Cameroon<\/p>

12:00 PM Eastern<\/p>

Poster Session B<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

6984 Madagascar E-Learning for the 2024 ITN Mass Campaign<\/p>

Poster Session B<\/p>

12:00 PM Eastern<\/p>

Location: Convention Center \u2013 Hall E (Level 8 Poster Hall)<\/p>

See abstract<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/path><\/svg><\/span>\n\t\t\t\t\t\t\t\t<\/path><\/svg><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tNovember 12<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Poster Presentations<\/strong><\/p>

(7471) Emergence of a validated Plasmodium falciparum Kelch 13 mutation (A675V) associated with artemisinin partial resistance and low prevalence of pfhrp2\/3 deletions in Cameroon<\/p>

11:00 AM Eastern<\/p>

Poster Session C<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(7479) Private sector readiness for multiple first-line therapies for malaria: data from three countries<\/p>

Poster Session C\u00a0<\/p>

Convention Center \u2013 Hall E (Level 8 Poster Hall)<\/p>

11:00 AM Eastern<\/p>

See abstract<\/a><\/p>

(7493) Antimalarial and diagnostic test market landscape in Cameroon\u2019s private sector: Insights from ACTwatch Lite in Central and Littoral regions<\/p>

Poster Session C\u00a0<\/span><\/p>

11:00 AM Eastern<\/p>

Convention Center \u2013 Hall E (Level 8 Poster Hall)<\/p>

See abstract<\/a><\/p>

(7566) Time from asymptomatic malaria infection to onset of symptoms in retrospective PCR analysis of samples collected among children over 63 days: Evidence from two randomised placebo-controlled trials of malaria chemoprevention in Zambia and Cameroon<\/p>

11:00 AM Eastern<\/p>

Poster Session C<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(7567) Positive Contribution of Efficient Logistics Coordination on the Reduction of Malaria Incidence Rates: Assessment of Mass Distribution Campaigns of Insecticide-Treated Nets in Madagascar<\/p>

Poster Session C<\/p>

11:00 AM Eastern<\/p>

Convention Center \u2013 Hall E (Level 8 Poster Hall)<\/p>

See abstract<\/a><\/p>

(7571) Implementation of perennial malaria chemoprevention in Cameroon: coverage, equity of coverage and change in coverage of co-interventions<\/p>

11:00 AM Eastern<\/p>

Poster Session C<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p>

(7577) Implementation of perennial malaria chemoprevention in Benin and Cote d\u2019Ivoire: what are the determinants of co-delivery of doses with childhood vaccinations in the first and second years of life?<\/p>

11:00 AM Eastern<\/p>

Poster Session C<\/p>

Convention Center \u2013 Hall E (Level 8) (Poster Hall)<\/p>

See abstract<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

9 – 13 November 2025 Join PSI at ASTMH 2025 Learn how PSI and our partners are advancing science and systems to end malaria. How can evidence and innovation accelerate progress toward ending malaria? PSI is sharing research and learnings from Benin, Cameroon, C\u00f4te d\u2019Ivoire, Democratic Republic of the Congo, Ghana, Madagascar, Mozambique, Zambia, and […]<\/p>\n","protected":false},"author":120,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-64271","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/pages\/64271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/users\/120"}],"replies":[{"embeddable":true,"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/comments?post=64271"}],"version-history":[{"count":0,"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/pages\/64271\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.psi.org\/fr\/wp-json\/wp\/v2\/media?parent=64271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}